Literature DB >> 11413148

Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells.

S Mahajan1, A Vassilev, N Sun, Z Ozer, C Mao, F M Uckun.   

Abstract

STAT5A is a molecular regulator of proliferation, differentiation, and apoptosis in lymphohematopoietic cells. Here we show that STAT5A can serve as a functional substrate of Bruton's tyrosine kinase (BTK). Purified recombinant BTK was capable of directly binding purified recombinant STAT5A with high affinity (K(d) = 44 nm), as determined by surface plasmon resonance using a BIAcore biosensor system. BTK was also capable of tyrosine-phosphorylating ectopically expressed recombinant STAT5A on Tyr(694) both in vitro and in vivo in a Janus kinase 3-independent fashion. BTK phosphorylated the Y665F, Y668F, and Y682F,Y683F mutants but not the Y694F mutant of STAT5A. STAT5A mutations in the Src homology 2 (SH2) and SH3 domains did not alter the BTK-mediated tyrosine phosphorylation. Recombinant BTK proteins with mutant pleckstrin homology, SH2, or SH3 domains were capable of phosphorylating STAT5A, whereas recombinant BTK proteins with SH1/kinase domain mutations were not. In pull-down experiments, only full-length BTK and its SH1/kinase domain (but not the pleckstrin homology, SH2, or SH3 domains) were capable of binding STAT5A. Ectopically expressed BTK kinase domain was capable of tyrosine-phosphorylating STAT5A both in vitro and in vivo. BTK-mediated tyrosine phosphorylation of ectopically expressed wild type (but not Tyr(694) mutant) STAT5A enhanced its DNA binding activity. In BTK-competent chicken B cells, anti-IgM-stimulated tyrosine phosphorylation of STAT5 protein was prevented by pretreatment with the BTK inhibitor LFM-A13 but not by pretreatment with the JAK3 inhibitor HI-P131. B cell antigen receptor ligation resulted in enhanced tyrosine phosphorylation of STAT5 in BTK-deficient chicken B cells reconstituted with wild type human BTK but not in BTK-deficient chicken B cells reconstituted with kinase-inactive mutant BTK. Similarly, anti-IgM stimulation resulted in enhanced tyrosine phosphorylation of STAT5A in BTK-competent B cells from wild type mice but not in BTK-deficient B cells from XID mice. In contrast to B cells from XID mice, B cells from JAK3 knockout mice showed a normal STAT5A phosphorylation response to anti-IgM stimulation. These findings provide unprecedented experimental evidence that BTK plays a nonredundant and pivotal role in B cell antigen receptor-mediated STAT5A activation in B cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413148     DOI: 10.1074/jbc.M104874200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

3.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

4.  Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.

Authors:  Jaya Rajaiya; Jamee C Nixon; Neil Ayers; Zana P Desgranges; Ananda L Roy; Carol F Webb
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

5.  STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Lisa Tuel-Ahlgren; Zahide Ozer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-29       Impact factor: 11.205

6.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.

Authors:  Mingye Feng; James Y Chen; Rachel Weissman-Tsukamoto; Jens-Peter Volkmer; Po Yi Ho; Kelly M McKenna; Samuel Cheshier; Michael Zhang; Nan Guo; Phung Gip; Siddhartha S Mitra; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 8.  Toll-like receptor function in primary B cell defects.

Authors:  Thomas U Marron; Joyce E Yu; Charlotte Cunningham-Rundles
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

9.  Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.

Authors:  Niklas Feldhahn; Florian Klein; Jana L Mooster; Paul Hadweh; Mieke Sprangers; Maria Wartenberg; Mohamed M Bekhite; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; Janet D Rowley; Markus Müschen
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

10.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.